BETAAccess all features while we're in beta! Some features may become paid later.Send feedback →
vpside

INM

InMed Pharmaceuticals Inc.
Nasdaq · Pharmaceutical preparations (SIC 2834) · FY ends 30 Jun

Revenue, quarterly

$820188−26.2% year on year
$3M$2M$1M$0
Q3 ’21Q4 ’22Q1 ’24Q1 ’25Q2 ’26
Company filings · 10-Q filed 11 Feb 2026 · Q4 = FY − 9Mvpside.com

Gross margin, trailing twelve months

29.7%−5.7 pp year on year
60%40%20%0%
Q1 ’23Q4 ’23Q4 ’24Q3 ’25Q2 ’26
Company filings · 10-Q filed 11 Feb 2026 · TTM = last four quartersvpside.com

Cash and cash equivalents, quarter-end

$2M−79.6% year on year
$20M$10M$0
Q1 ’22Q2 ’23Q3 ’24Q3 ’25Q4 ’26
Company filings · 10-K filed 9 Sept 2026 · balance sheet, period-endvpside.com

Free cash flow, trailing twelve months

−$16M
$10M$0−$10M−$20M
Q4 ’22
Company filings · 10-K filed 29 Sept 2023 · TTM = last four quartersvpside.com
Chart 05 is empty
Chart 06 is empty